MCE products for research use only. We do not sell to patients.

Polyinosinic-polycytidylic acid sodium

MCE China：Polyinosinic-polycytidylic acid sodium

Brand：MedChemExpress (MCE)

Cat. No.HY-135748

CAS：42424-50-0

Synonyms：Poly(I:C) sodium

Purity：99.40%

Storage：-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.

In Vitro：Polyinosinic-polycytidylic acid (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9 and 1205Lu cells) treatment strongly reduces viability from 100% in controls to 20%–50% within 24 hours[1]. Polyinosinic-polycytidylic acid (200 ng/mL; 24 hours; 1205Lu cells) treatment induces apoptosis in 1205Lu cells[1]. Polyinosinic-polycytidylic acid (3 ng/mL; 24 hours; 1205Lu cells) treatment induces IFN-β expression in melanoma cells. Silencing of RIG-I and MDA-5 confirmed that induction of IFN-β by Polyinosinic-polycytidylic acid required RIG-I and MDA-5, respectively, and that required IPS-1[1]. Polyinosinic-polycytidylic acid (5 ng/mL; 24 hours; 1205Lu cells) treatment reveals active subunits of caspase-9 and caspase-8 in melanoma cells[1]. Polyinosinic-polycytidylic acid sodium is prepared for injection by resuspending in sterile saline, heating to 50 °C at a concentration of 2 mg/mL to ensure complete solubilisation and then allowing to cool naturally to room temperature to ensure proper annealing of double-stranded RNA. Polyinosinic-polycytidylic acid is stored at -20 °C until use[3].

In Vivo：Polyinosinic-polycytidylic acid treatment inhibits tumor growth in NOD/SCID immunodeficient mice injected with 1205Lu cells. The level of human DNA is 50% lower in mice treated with Polyinosinic-polycytidylic acid[1].

IC50 & Target：TLR3

Hot selling product：Benzetimide (hydrochloride)  | Ranirestat  | CGP77675  | 9-Phenanthrol  | DBCO-PEG4-triethoxysilane  | Roxithromycin-d7  | Physostigmine (hemisulfate)  | Sutimlimab  | Tusamitamab  | Cobimetinib (R-enantiomer)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.  [Content Brief]

[2]. Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.  [Content Brief]

[3]. Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.  [Content Brief]